Leading pharmacy benefit managers (PBMs) recently released updates to their 2019 national formularies. For 2019, Express Scripts Holding Co. will exclude 48 drugs from its national preferred formulary, including hepatitis C drug Mavyret and HIV drug Atripla. Meanwhile, CVS Health and OptumRx cut 23 and 36 medications from their 2019 formularies, respectively. According to a recent Solid Benefit Guidance white paper, the changes are likely to negatively impact 0.2% to 1.24% of members, as estimated by two of the three largest national PBMs.
SOURCES: Solid Benefit Guidance; Express Scripts Holding Co.; CVS Health; OptumRx, Inc.